We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

NIS-observe Treatment Efficacy in Maintaining Symptoms Control in Moderate/Severe Asthma With Symbicort SMART

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00785733
First Posted: November 5, 2008
Last Update Posted: December 2, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
  Purpose
The primary objective of this non-interventional study is to evaluate efficacy of Symbicort® SMART treatment in adult patients with moderate to severe asthma using ACQ scores during 6 months period

Condition
Moderate/Severe Asthma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: SMART Way of Treating Asthma. Non-interventional Study to Evaluate Clinical Efficacy of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Patients With Moderate and Severe Asthma

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Asthma Control Questionnaire ACQ [ Time Frame: 5 visits (V1-week 0, V2-week 4, V3-week 8, V4-week 16, V5-week 24) ]

Enrollment: 1182
Study Start Date: November 2008
Study Completion Date: October 2009
Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Moderate and severe asthma patients stabilized on Symbicort SMART

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
The programme will include patients with moderate and severe asthma stabilized on Symbicort SMART from community sample
Criteria

Inclusion Criteria:

  • patients eligible for entry into study are the patients diagnosed with moderate to severe asthma, that the doctors have already decided to treat with Symbicort SMART within the last month, before inclusion in this program
  • All eligible patients will be included in the protocol provided they will receive detailed information in advance and will sign consent to grant access to their own data collected during this programme.

Exclusion Criteria:

  • All the patients who have a known hypersensitivity to Symbicort or any of its excipients will not be included in this study.
  • As per valid Romanian SmPC, concomitant medication, that could result in drug interactions and could jeopardise patient safety will be carefully considered before having the patient enrolled.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00785733


Locations
Romania
Research Site
Alba Iulia, Romania
Research Site
Alexandria, Romania
Research Site
Arad, Romania
Research Site
Bacau, Romania
Research Site
Baia Mare, Romania
Research Site
Botosani, Romania
Research Site
Braila, Romania
Research Site
Brasov, Romania
Research Site
Breaza, Romania
Research Site
Bucuresti, Romania
Research Site
Buftea, Romania
Research Site
Calarasi, Romania
Research Site
Campina, Romania
Research Site
Campulung, Romania
Research Site
Cluj Napoca, Romania
Research Site
Constanta, Romania
Research Site
Craiova, Romania
Research Site
Deva, Romania
Research Site
Drobeta Turnu Severin, Romania
Research Site
Giurgiu, Romania
Research Site
Hunedoara, Romania
Research Site
Iasi, Romania
Research Site
Leordeni, Romania
Research Site
Miercurea Ciuc, Romania
Research Site
Mizil, Romania
Research Site
Oradea, Romania
Research Site
Palazu Mare, Romania
Research Site
Piatra Neamt, Romania
Research Site
Pitesti, Romania
Research Site
Ploiesti, Romania
Research Site
Resita, Romania
Research Site
Rm. Valcea, Romania
Research Site
Scornicesti, Romania
Research Site
Sf. Gheorghe, Romania
Research Site
Sibiu, Romania
Research Site
Slobozia, Romania
Research Site
Suceava, Romania
Research Site
Targoviste, Romania
Research Site
Targu Mures, Romania
Research Site
Tg. Jiu, Romania
Research Site
Timisoara, Romania
Research Site
Tulcea, Romania
Research Site
Vaslui, Romania
Research Site
Zalau, Romania
Sponsors and Collaborators
AstraZeneca
Investigators
Study Chair: Cristina Pentiuc AstraZeneca
  More Information

Responsible Party: Cristina Pentiuc, Medical Science Director, AstraZeneca
ClinicalTrials.gov Identifier: NCT00785733     History of Changes
Other Study ID Numbers: NIS-RRO-SYM-2008/1
First Submitted: November 4, 2008
First Posted: November 5, 2008
Last Update Posted: December 2, 2010
Last Verified: November 2010

Keywords provided by AstraZeneca:
asthma

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Budesonide, Formoterol Fumarate Drug Combination
Anti-Asthmatic Agents
Respiratory System Agents